Cellebrite CLBT
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 82nd percentile, 5-year average 3.2x
#2533 of 2993 stocks by PE (1 = cheapest)
Below its usual level · 24th percentile, 5-year average 8.1x
#4385 of 5330 stocks by PB (1 = cheapest)
Around its usual level · 42nd percentile, 5-year average 6.2x
#4011 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 5.00 | – | 8.13 | 24% (cheaper than usual) | #4385 of 5330 (1 = cheapest) |
| PE | 46.12 | 35.06 | 3.23 | 82% (pricier than usual) | #2533 of 2993 (1 = cheapest) |
| PS | 5.39 | 4.77 | 6.19 | 42% (cheaper than usual) | #4011 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on CLBT.
Sign in to join the discussion.